西酞普兰联合利培酮治疗难治性抑郁症的疗效与安全性分析

目的 探讨西酞普兰联合小剂量利培酮治疗难治性抑郁症的疗效及安全性.方法 将54例难治性抑郁症患者随机分为两组,西酞普兰联合利培酮组:西酞普兰(20 mg/d)治疗的同时联合应用利培酮(0.5～2.0mg/d),共28例.西酞普兰组:单用西酞普兰(20mg/d)治疗,共26例.两组持续治疗6周.于治疗前及治疗第2、4、6周末应用汉密尔顿抑郁量表(HAMD,17项)和汉密尔顿焦虑量表(HAMA)以及不良反应量表(TESS)进行评定.结果 西酞普兰联合利培酮组总有效率为60.7%,痊愈和显效占50.0%;西酞普兰组的总有效率为26.9%,痊愈和显效占15.4%,两组总有效率比较差异有统计学意义(P<0.05).两组患者的不良反应均轻微.结论 西酞普兰联合小剂量利培酮治疗难治性抑郁症的疗效优于单用西酞普兰,且安全性较好,是临床治疗中可选用的方法之一.

Effects and safety of citalopram combined with low-dose risperidone on refractory depression

Objective To explore the effects and safety of citalopram combined with low-dose risperidone on refractory depression. Methods All of 54 patients with the refractory depression were ran-domly divided into two groups: augmented treatment group (taken citalopram 20 mg/d, risperidone 0.5-2.0mg/d) and mono-thempy group (taken citalopram alone 20 mg/d). The treatment lasted for 6 weeks. They were estimated with Hamilton depression scale (HAMD), Hamilton anxiety scale (HAMA), and treatment emergent symptom scale (TESS) at baseline and every two weeks subsequently. Results In the augment-ed treatment group, total effective rate was 60.7% and recovery and excellence rate was 50.0%, while that was 26.9% and 15.4% in mono-therapy group (P< 0.05). The adverse effect of two groups was minor. Conclu-sion Rispefidone may be a useful and safe adjunct to citalopram in treatment of refractory depression.